Table 1 Blood lipid levels and lipid-lowering strategies of the proband

6-24-2020

12.79

10.68

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

baseline levels without any medication

6-29-2020

10.07 (−21.3%)

8.31 (−22.2%)

49.1

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

just before LA

6-29-2020

3.29 (−74.2%)

2.56 (−76.0%)

14.2 (−71.1%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

LA

immediately after LA

6-30-2020

3.81 (−70.2%)

2.78 (−74.0%)

20.1 (−59.1%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

7-1-2020

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

PCI at LAD

7-3-2020

4.59 (−64.1%)

3.35 (−68.6%)

evolocumab 420 mg SC

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

7-7-2020

3.83 (−70.1%)

2.79 (−73.9%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

7-14-2020

3.57 (−72.1%)

2.22 (−79.2%)

30.6 (−37.7%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

15 days after LA and 11 days after evolocumab 420 mg

7-27-2020

4.5 (−64.8%)

2.93 (−72.6%)

18.1 (−63.1%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

8-17-2020

5.21 (−59.3%)

3.49 (−67.3%)

39.5 (−19.6%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

9-14-2020

5.36 (−58.1%)

3.66 (−65.7%)

40.9 (−16.7%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

9-19-2020

evolocumab 140 mg SC

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

10-13-2020

evolocumab 140 mg SC

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

10-17-2020

evolocumab 140 mg SC

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

10-20-2020

4.28 (−66.5%)

2.81 (−73.7%)

25.5 (−48%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

3-9-2021

7.18 (−43.9%)

5.67 (−46.9%)

24.7 (−49.7%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

9-27-2021

6.15 (−51.9%)

4.70 (−56.0)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

10-26-2021

4.63 (−64.6%)

3.17 (−70.3%)

22.6 (−54.0%)

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

10-27-2021

rosuvastatin 20 mg qd

ezetimibe 10 mg qd

PCI at RCA